

Veloxa XL Chewable Tablets for Dogs

Authorised

- Febantel
- Pyrantel
- Praziquantel

Product identification

Medicine name:

Veloxa XL Chewable Tablets for Dogs

Active substance:

Febantel

Pyrantel

Praziquantel

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Febantel

525.00 milligram(s) / 1.00 Tablet

Pyrantel

175.00 milligram(s) / 1.00 Tablet

Praziquantel

175.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP52AA51

Legal status of supply:

Veterinary medicinal product not subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

United Kingdom (Northern Ireland)

Package description:

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 1 blister strip of 2 chewable tablets (2 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 2 blister strips of 2 chewable tablets (4 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 4 blister strips of 2 chewable tablets (8 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 24 blister strips of 2 chewable tablets (48 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 48 blister strips of 2 chewable tablets (96 chewable tablets)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Lavet Kft.

Marketing authorisation date:

16/01/2013

Manufacturing sites for batch release:

Lavet Kft.

Responsible authority:

The Veterinary Medicines Directorate

Authorisation number:

Vm 32823/4011

Date of authorisation status change:

16/05/2024

Reference member state:

Hungary

Procedure number:

HU/V/0116/002

Concerned member states:

Austria Belgium Finland France Germany Greece Ireland Italy Luxembourg
Netherlands Norway Portugal Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics